2,622 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Wealthspire Advisors LLC

Wealthspire Advisors LLC acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,622 shares of the biopharmaceutical company’s stock, valued at approximately $219,000.

Several other large investors also recently bought and sold shares of ITCI. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC grew its position in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $74,000. Venturi Wealth Management LLC purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $97,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Piper Sandler reissued a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $106.08.

Insider Activity

In other news, CEO Sharon Mates sold 51,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $128.25 on Friday. The firm has a market cap of $13.64 billion, a PE ratio of -147.41 and a beta of 0.72. The company has a 50-day moving average of $112.80 and a two-hundred day moving average of $90.87. Intra-Cellular Therapies, Inc. has a 1-year low of $63.30 and a 1-year high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.